
Sign up to save your podcasts
Or
AstraZeneca’s Covid vaccine is the third one to prove highly effective in late-stage trials. AstraZeneca Executive Vice President Ruud Dobber explains differentiators of his company’s vaccine, and why between his company, Pfizer, and Moderna, he has high hopes for an accessible vaccine. New York Times columnist Thomas Friedman discusses the next steps in the race for a vaccine and in the Presidential transition. Plus, political pollster and strategist Frank Luntz unpacks what’s at stake on the ballots in Georgia.
4.2
505505 ratings
AstraZeneca’s Covid vaccine is the third one to prove highly effective in late-stage trials. AstraZeneca Executive Vice President Ruud Dobber explains differentiators of his company’s vaccine, and why between his company, Pfizer, and Moderna, he has high hopes for an accessible vaccine. New York Times columnist Thomas Friedman discusses the next steps in the race for a vaccine and in the Presidential transition. Plus, political pollster and strategist Frank Luntz unpacks what’s at stake on the ballots in Georgia.
4,081 Listeners
1,355 Listeners
239 Listeners
148 Listeners
328 Listeners
990 Listeners
68 Listeners
153 Listeners
2,137 Listeners
2,046 Listeners
598 Listeners
20 Listeners
1,542 Listeners
401 Listeners
302 Listeners
117 Listeners
792 Listeners
178 Listeners
60 Listeners
161 Listeners
21 Listeners
33 Listeners
11 Listeners
9 Listeners
261 Listeners
9 Listeners